Chinese specialty pharmaceutical firm Nuance Biotech has raised $181 million in a Series D round of financing to advance the R&D of the firm’s existing drug candidates and to explore new potential products.
The new round was jointly led by GT Fund, a state-backed private equity fund that invests in China’s cross-border companies in the healthcare, advanced manufacturing, and clean energy fields; as well as New York-based biopharma investment specialist RTW Investments, Nuance announced in a statement on December 8.
